Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Johnson & Johnson has reported Phase III data where CARVYKTI improved overall survival in patients with multiple myeloma.

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Multiple myeloma therapeutics industry is projected to witness a CAGR of 6.4% during the period 2024-2032. This growth can be ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated ...

A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma ...

Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other ...

Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes back.

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.